| Description | CFAP100 Human Pre-designed siRNA Set A contains three designed siRNAs for CFAP100 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CFAP100 siRNA-1: 5 nmol (HPLC) CFAP100 siRNA-2: 5 nmol (HPLC) CFAP100 siRNA-3: 5 nmol (HPLC) siRNA CFAP100 Human Pre-designed siRNA Set A contains three designed siRNAs for CFAP100 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CFAP100 siRNA-1: 5 nmol (HPLC) CFAP100 siRNA-2: 5 nmol (HPLC) CFAP100 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Biochemical Test:SDS-PAGE (purity > 80%); Western blot with patient sample.Calculated Isoelectric Point:pH 6.10 | Seals and prevents freezing of stopcocks and ground-glass joints in high-vacuum systems at pressures less than 10-6 mm Hg. Heat stable (?40 to 260 °C), low vapor pressure, and chemically resistant. Colorless. 5.3 oz. tube | Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis... Read More | Format:1-ComponentEnzyme:Horseradish peroxidase |